


What is claimed is:

1. A compound as shown in formula (II), a pharmaceutically acceptable salt thereof and a tautomer thereof,



X₂ is N, each of X₁ and X₃ is independently N or CH;

n is selected from 0 or 1;

R₁ is selected from H, F, Cl, Br, I, OH, NH₂, or selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ heteroalkyl, 3-6 membered heterocycloalkyl and 5-6 membered heteroaryl, each of which is optionally substituted by 1, 2 or 3 R;

R₂ is selected from H, F, Cl, Br, I;

R₃ is selected from H, F, Cl, Br, I, OH, NH₂;

R is selected from F, Cl, Br, I, OH, NH₂, or selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ alkoxy and 3-6 membered heterocycloalkyl, each of which is optionally substituted by 1, 2 or 3 R';

R' is selected from the group consisting of F, Cl, Br, I, OH, NH₂ and C₁₋₃ alkyl;


each of the "hetero" in the C₁₋₄ heteroalkyl, 5-6 membered heteroaryl and 3-6 membered heterocycloalkyl is independently selected from the group consisting of -NH-, N, -O-, and -S-;

in any of the above cases, the number of the "hetero" is independently selected from 1, 2 or 3.

2. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to claim 1, wherein, R is selected from F, Cl, Br, I, OH, NH₂, or



selected from the group consisting of Me, , and , each of which is optionally substituted by 1, 2 or 3 R'.

3. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to claim 2, wherein, R is selected from F, Cl, Br, I, OH, NH₂, Me,





4. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to any one of claims 1-3, wherein, R₁ is selected from H, F, Cl, Br, I, OH, NH₂, or selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ alkylamino, morpholinyl and pyridyl, each of which is optionally substituted by 1, 2 or 3 R.






5. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to claim 4, wherein, R₁ is selected from H, F, Cl, Br, I, OH, NH₂, or

selected from the group consisting of Me, , , , ,  and , each of which is optionally substituted by 1, 2 or 3 R.




6. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to claim 5, wherein, R₁ is selected from H, F, Cl, Br, I, OH, NH₂,

Me, , , , , , , ,  and .


7. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to any one of claims 1-3, wherein, the moiety

 is selected from the group consisting of , ,  and .

8. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to any one of claims 1-3, wherein, the moiety

 is selected from the group consisting of  and .

9. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to any one of claims 1-6 is selected from the group consisting of




wherein,

X₁, X₂, X₃, R₂ and R₃ are defined as claim 1;

R₁ is defined as any one of claims 1 and 4-6.

10. The compound, the pharmaceutically acceptable salt thereof and the tautomer thereof according to claim 9, which is selected from the group consisting of





wherein,

R₂ and R₃ are defined as claim 1;

R₁ is defined as any one of claims 1 and 4-6.

11. A compound, a pharmaceutically acceptable salt thereof and a tautomer thereof which is selected from the group consisting of





12. A pharmaceutical composition, comprising a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-11 as the active ingredient, and a pharmaceutically acceptable carrier.

13. A use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-11 in manufacturing a medicament for treating ASK1-related diseases, wherein the ASK1-related diseases are neurodegenerative diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, or metabolic

disorders.

14. A use of the composition according to claim 12 in manufacturing a medicament for treating ASK1-related diseases, wherein the ASK1-related diseases are neurodegenerative diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, or metabolic disorders.